Proadifen hydrochloride

CAS No. 62-68-0

Proadifen hydrochloride( RP 5171 | U 5446 )

Catalog No. M15371 CAS No. 62-68-0

Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 31 In Stock
100MG 27 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Proadifen hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM).
  • Description
    Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    RP 5171 | U 5446
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    P450
  • Recptor
    CYP
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    62-68-0
  • Formula Weight
    389.96
  • Molecular Formula
    C23H32ClNO2
  • Purity
    >98% (HPLC)
  • Solubility
    Soluble in DMSO
  • SMILES
    O=C(OCCN(CC)CC)C(CCC)(C1=CC=CC=C1)C2=CC=CC=C2.[H]Cl
  • Chemical Name
    Benzeneacetic acid, alpha-phenyl-alpha-propyl-, 2-(diethylamino)ethyl ester, hydrochloride

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Viana AP, Osswald W. Arzneimittelforschung. 1970 Jun;20(6):851-3.
molnova catalog
related products
  • Guan-fu base A hydro...

    Guan-fu base A hydrochloride is an antiarrhythmic alkaloid was isolated from Aconitum coreanum. Guanfu base A is hydrochloride a CYP2D6 inhibitor of human, monkey, and dog isoforms.

  • DMU2139

    DMU2139 is a specific CYP1B1 inhibitor (CYP1B1 and CYP1A1 with IC50 of 9 nM and 795 nM, respectively).

  • CYP1B1-IN-7

    CYP1B1-IN-7 is a selective and potent CYP1B1 inhibitor showing cytotoxic effects in docetaxel-resistant CYP1B1 overexpressing MCF-7 cell lines, and can be used in synergistic treatment of cancer with anticancer compounds.